BRPI0507683A - dose unitária com liberação de formulação farmacêutica com liberação controlada, processo para sua preparação, bem como uso de um copolìmero de poli(acrilato de etila, metacrilato de metila) neutro - Google Patents

dose unitária com liberação de formulação farmacêutica com liberação controlada, processo para sua preparação, bem como uso de um copolìmero de poli(acrilato de etila, metacrilato de metila) neutro

Info

Publication number
BRPI0507683A
BRPI0507683A BRPI0507683-8A BRPI0507683A BRPI0507683A BR PI0507683 A BRPI0507683 A BR PI0507683A BR PI0507683 A BRPI0507683 A BR PI0507683A BR PI0507683 A BRPI0507683 A BR PI0507683A
Authority
BR
Brazil
Prior art keywords
copolymer
methyl methacrylate
preparation
well
unit dose
Prior art date
Application number
BRPI0507683-8A
Other languages
English (en)
Inventor
Geoffrey Gerard Hayes
Helen Kathleen Danagher
Hassan Mohammad
Derek Allan Prater
Harjit Tamber
Malcolm Walden
Steve Whitelock
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34889127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507683(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0403100A external-priority patent/GB0403100D0/en
Priority claimed from GBGB0501638.1A external-priority patent/GB0501638D0/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BRPI0507683A publication Critical patent/BRPI0507683A/pt
Publication of BRPI0507683A8 publication Critical patent/BRPI0507683A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00—Making granules
    • B29B9/02—Making granules by dividing preformed material
    • B29B9/06—Making granules by dividing preformed material in the form of filamentary material, e.g. combined with extrusion
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2033/00—Use of polymers of unsaturated acids or derivatives thereof as moulding material
    • B29K2033/04—Polymers of esters
    • B29K2033/12—Polymers of methacrylic acid esters, e.g. PMMA, i.e. polymethylmethacrylate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0085—Copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Mechanical Engineering (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DOSE UNITáRIA COM LIBERAçãO DE FORMULAçãO FARMACêUTICA COM LIBERAçãO CONTROLADA, PROCESSO PARA SUA PREPARAçãO, BEM COMO USO DE UM COPOLìMERO DE POLI(ACRILATO DE ETILA, METACRILATO DE METILA) NEUTRO. Emprega-se um copolímero de poli(acrilato de etila, metacrilato de metila) neutro como um veículo na fabricação de formulações farmacêuticas contendo um ingrediente ativo. As formulações são preparadas, de preferência, por extrusão em fusão e podem ter características de borracha e podem exibir resistência à adulteração.
BRPI0507683A 2004-02-12 2005-02-11 dose unitária de formulação farmacêutica com liberação controlada, seu processo de preparação e uso de um copolímero de poli(acrilato de etila, metacrilato de metila) neutro BRPI0507683A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0403100A GB0403100D0 (en) 2004-02-12 2004-02-12 Particulates
GBGB0501638.1A GB0501638D0 (en) 2005-01-28 2005-01-28 Particulates
PCT/GB2005/050014 WO2005079760A1 (en) 2004-02-12 2005-02-11 Particulates

Publications (2)

Publication Number Publication Date
BRPI0507683A true BRPI0507683A (pt) 2007-07-17
BRPI0507683A8 BRPI0507683A8 (pt) 2018-12-26

Family

ID=34889127

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507683A BRPI0507683A8 (pt) 2004-02-12 2005-02-11 dose unitária de formulação farmacêutica com liberação controlada, seu processo de preparação e uso de um copolímero de poli(acrilato de etila, metacrilato de metila) neutro

Country Status (16)

Country Link
US (5) US8920836B2 (pt)
EP (1) EP1729731A1 (pt)
JP (2) JP5122823B2 (pt)
KR (1) KR101189038B1 (pt)
AR (1) AR047540A1 (pt)
AU (1) AU2005215239B2 (pt)
BR (1) BRPI0507683A8 (pt)
CA (1) CA2555423C (pt)
EA (1) EA200601468A1 (pt)
IL (1) IL177313A (pt)
NO (1) NO20064094L (pt)
NZ (1) NZ548962A (pt)
PE (2) PE20091898A1 (pt)
TW (1) TWI350762B (pt)
UY (1) UY28744A1 (pt)
WO (1) WO2005079760A1 (pt)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1041987B1 (en) 1997-12-22 2006-04-19 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
EP1991207A2 (en) * 2006-01-21 2008-11-19 Abbott GmbH & Co. KG Dosage form and method for the delivery of drugs of abuse
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
RU2465916C2 (ru) * 2007-10-19 2012-11-10 Оцука Фармасьютикал Ко., Лтд. Твердый фармацевтический препарат матричного типа
TW200950776A (en) * 2008-01-24 2009-12-16 Abbott Gmbh & Co Kg Abuse resistant melt extruded formulation having reduced alcohol interaction
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
AU2009243681B2 (en) 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
WO2010017056A1 (en) * 2008-08-07 2010-02-11 Merck & Co., Inc. Orally administered solid formulations containing a hydrophobic drug and tpgs
EP2334287A4 (en) * 2008-08-20 2013-12-25 Univ Texas MELT EXTRUSION OF MULTIPARTICLES WITH MODIFIED RELEASE
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
TWI473628B (zh) 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
CN103002881B (zh) 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
AU2011252039B2 (en) 2010-05-10 2014-06-12 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
EP2612657B1 (en) * 2010-08-31 2023-08-09 Kyowa Kirin Co., Ltd. Orodispersible tablet
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
US20120202838A1 (en) 2010-11-04 2012-08-09 Abbott Laboratories Drug formulations
EP2635247B1 (en) 2010-11-04 2016-12-14 AbbVie Inc. Method for producing monolithic tablets
GB201020895D0 (en) * 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
CN103501767A (zh) 2011-06-17 2014-01-08 赢创罗姆有限公司 适合于药物或营养制品剂型的包衣组合物
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
BR112014009033A2 (pt) * 2011-10-18 2017-10-17 Purdue Pharma Lp formulações de polímero acrílico
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
BR112015000320B1 (pt) 2012-07-12 2023-03-07 SpecGx LLC Composições farmacêuticas dissuasivas de abuso e seu processo de preparação
KR101659983B1 (ko) * 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
CA2905159C (en) * 2013-03-15 2023-01-03 Aptalis Pharma Ltd. Composition containing digestive enzymes and nutrients suitable for enteral administration
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
MX2018011799A (es) * 2016-03-31 2019-01-24 SpecGx LLC Formas de dosificacion de liberacion prolongada disuasivas de abuso.
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2018118903A1 (en) 2016-12-19 2018-06-28 The Regents Of The University Of California Noncrushable pill formulatiions
US11879019B2 (en) 2016-12-19 2024-01-23 The Regents Of The University Of California Dual-enzyme responsive peptides
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019038430A1 (en) * 2017-08-25 2019-02-28 Eleonor Sprl COMPOSITION COMPRISING AT LEAST ONE PROTOBERBERIN ALKALOID AND METHOD FOR PRODUCING THE SAME
JP2020536930A (ja) * 2017-10-13 2020-12-17 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 放出調節乱用防止剤形
CA3166250A1 (en) 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof
CN117224497A (zh) * 2023-10-26 2023-12-15 山东丰金生物医药有限公司 一种稳定的碳酸司维拉姆片剂组合物及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080134A (en) 1975-09-23 1978-03-21 Mobil Oil Corporation Apparatus for pelletizing plastic material
GB1603640A (en) 1977-07-20 1981-11-25 Gist Brocades Nv Enzyme particles
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
JPH07112697B2 (ja) 1989-08-18 1995-12-06 三菱レイヨン株式会社 熱可塑性樹脂球状粒子の製造法
US5085815A (en) 1989-12-26 1992-02-04 Exxon Chemical Patents Inc. Process of recovering and conveying shaped polymer extrudate
FR2663818B1 (fr) 1990-06-29 1993-07-09 Rhone Poulenc Nutrition Animale Procede de preparation de granules de principes actifs par extrusion.
ZA919510B (en) 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
DE4138513A1 (de) * 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
US5500161A (en) * 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19504119C2 (de) 1995-02-08 2000-07-13 S Rockstedt Gmbh Maschf Am Ausgang eines Extruders angebrachter Düsenkopf
ATE255883T1 (de) 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
JP2002511777A (ja) 1996-10-28 2002-04-16 ゼネラル ミルズ，インコーポレイテッド 調放性粒子の埋包およびカプセル化
US6013272A (en) 1996-12-19 2000-01-11 Valent U.S.A. Corporation Chemically stable, insecticidally active phosphoroamidothioate pellet compositions and methods for their manufacture
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
AU781058B2 (en) 1999-08-31 2005-05-05 Grunenthal Gmbh Delayed-action form of administration containing tramadol saccharinate
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US6712789B1 (en) 2000-07-13 2004-03-30 Medamicus, Inc. Introducer having a movable valve assembly with removable side port
MXPA03003895A (es) * 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
WO2003004009A1 (en) * 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
BR0212019A (pt) * 2001-08-06 2005-08-09 Euro Celtique Sa Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
US7691430B2 (en) 2001-11-07 2010-04-06 Medwell Foods, Inc. Food material technology with controllable functional characteristics and industrial process applications, and the resulting fabricated foods
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20060165790A1 (en) 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GEP20105052B (en) 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms

Also Published As

Publication number Publication date
US20120141583A1 (en) 2012-06-07
CA2555423C (en) 2018-07-24
UY28744A1 (es) 2005-08-31
IL177313A0 (en) 2006-12-10
WO2005079760A1 (en) 2005-09-01
AU2005215239A1 (en) 2005-09-01
EA200601468A1 (ru) 2007-02-27
KR101189038B1 (ko) 2012-10-08
JP2012193186A (ja) 2012-10-11
NO20064094L (no) 2006-11-10
NZ548962A (en) 2010-08-27
TW200529888A (en) 2005-09-16
US20070298103A1 (en) 2007-12-27
CA2555423A1 (en) 2005-09-01
KR20070029673A (ko) 2007-03-14
IL177313A (en) 2014-11-30
US20150148366A1 (en) 2015-05-28
JP2007522196A (ja) 2007-08-09
EP1729731A1 (en) 2006-12-13
JP5746664B2 (ja) 2015-07-08
TWI350762B (en) 2011-10-21
US20180153812A1 (en) 2018-06-07
BRPI0507683A8 (pt) 2018-12-26
US8920836B2 (en) 2014-12-30
PE20091898A1 (es) 2009-12-31
AR047540A1 (es) 2006-01-25
AU2005215239B2 (en) 2011-03-24
US20170079923A1 (en) 2017-03-23
PE20050775A1 (es) 2005-11-28
JP5122823B2 (ja) 2013-01-16

Similar Documents

Publication Publication Date Title
BRPI0507683A (pt) dose unitária com liberação de formulação farmacêutica com liberação controlada, processo para sua preparação, bem como uso de um copolìmero de poli(acrilato de etila, metacrilato de metila) neutro
HN2000000267A (es) Oxazolidinonas substituidas y su uso
AR097045A2 (es) Sistema terapéutico transdérmico
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
BRPI0408243A (pt) método para fabricação de partìculas de polìmeros superabsorvente de cor estável, partìculas superabsorventes de cor estável, artigo absorvente, e, fralda
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
ATE344022T1 (de) Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
CY1106943T1 (el) Υποδορια εμφυτευματα τα οποια εμφανιζουν περιορισμενη αρχικη αποδεσμευση του ενεργου συστατικου και ακολουθως γραμμικα μεταβαλλομενη εκτεταμενη αποδεσμευση
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
BRPI0510654A (pt) formulações de interferon em hidrogel
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
EA200401369A1 (ru) Замедленно высвобождающие лекарственные композиции гвайфенезина
SE0302546D0 (sv) New compounds
AU2003230189A1 (en) Oral controlled release pharmaceutical composition containing metaxalone as active agent
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EA200901148A1 (ru) Подкожные имплантаты, высвобождающие активные компоненты в течение длительного периода времени
BRPI0405662A (pt) Emplastros contendo turobuterol
UY28537A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
DE602005027194D1 (de) Buttersäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und therapeutische anwendungen davon
DK1537132T3 (da) Salt af mortin-6-glucuronid

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements